169 related articles for article (PubMed ID: 17573199)
1. Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?
Ding H; Field TS
Cancer Treat Rev; 2007 Oct; 33(6):506-13. PubMed ID: 17573199
[TBL] [Abstract][Full Text] [Related]
2. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
3. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
5. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Coleman RE; Body JJ; Gralow JR; Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
7. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
[TBL] [Abstract][Full Text] [Related]
8. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
[TBL] [Abstract][Full Text] [Related]
9. [Effect of aromatase inhibitors on bone metabolism].
Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Hadji P; Bundred N
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
[TBL] [Abstract][Full Text] [Related]
11. Lignan-rich sesame seed negates the tumor-inhibitory effect of tamoxifen but maintains bone health in a postmenopausal athymic mouse model with estrogen-responsive breast tumors.
Sacco SM; Chen J; Power KA; Ward WE; Thompson LU
Menopause; 2008; 15(1):171-9. PubMed ID: 17545920
[TBL] [Abstract][Full Text] [Related]
12. Reducing the risk of bone loss associated with breast cancer treatment.
Hadji P
Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
[TBL] [Abstract][Full Text] [Related]
13. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen therapy in breast cancer control worldwide.
Love RR; Koroltchouk V
Bull World Health Organ; 1993; 71(6):795-803. PubMed ID: 8313498
[TBL] [Abstract][Full Text] [Related]
15. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
Litsas G
Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
17. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of tamoxifen in postmenopause.
Sismondi P; Biglia N; Giai M; Sgro L; Campagnoli C
Anticancer Res; 1994; 14(5B):2237-44. PubMed ID: 7840529
[TBL] [Abstract][Full Text] [Related]
19. Interaction of sesame seed and tamoxifen on tumor growth and bone health in athymic mice.
Sacco SM; Power KA; Chen J; Ward WE; Thompson LU
Exp Biol Med (Maywood); 2007 Jun; 232(6):754-61. PubMed ID: 17526767
[TBL] [Abstract][Full Text] [Related]
20. Management of bone loss induced by aromatase inhibitors.
Gnant M
Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
